Related content

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!

By  

Case Reports in Oncology, Vol. 5, Iss. 3, 2012-10 ,pp. : 586-591

Karger

Access to resources Recommend Favorite

Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 4, 2018-02 ,pp. : 526-533

John Wiley & Sons Inc

Access to resources Recommend Favorite

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 2015-10 ,pp. : 210-214

John Wiley & Sons Inc

Access to resources Recommend Favorite

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 2, 2015-10 ,pp. : 210-214

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-04 ,pp. : 277-284

Karger

Access to resources Recommend Favorite